Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00122811
Status:
UNKNOWN
Last Update Posted:
2007-08-21
First Post:
2005-07-13
Brief Title:
The Hypertension in the Very Elderly Trial HYVET
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
The Hypertension in the Very Elderly Trial HYVET
Status:
UNKNOWN
Status Verified Date:
2007-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the benefits and risks of treating very elderly those aged 80 or older individuals with hypertension
Detailed Description:
The benefit to risk ratio of treating hypertensives aged 80 or older has not been established It has been suggested that at this age for each stroke prevented there is one non-stroke death HYVET is designed to help clarify this
HYVET is a randomised double-blind placebo-controlled trial in hypertensive subjects aged 80 or older Active treatment consists of indapamide 15mg SR with the addition of perindopril 2mg - 4mg to reach a target blood pressure BP of 15080 mmHg Entry criteria include a systolic blood pressure of 160-199 mmHg Patients with isolated systolic hypertension ISH have been recruited since August 2003
HYVET is a randomised double-blind placebo-controlled trial in hypertensive subjects aged 80 or older Active treatment consists of indapamide 15mg SR with the addition of perindopril 2mg - 4mg to reach a target blood pressure BP of 15080 mmHg Entry criteria include a systolic blood pressure of 160-199 mmHg Patients with isolated systolic hypertension ISH have been recruited since August 2003
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None